- UDENYCA
ON-BODY INJECTOR
On-the-go treatment with a 5-minute injection time1
~90% faster medication delivery than Neulasta® Onpro®1-4
*Uses acrylic adhesive. For patients who have reactions to acrylic adhesives, use of this product may result in a significant reaction.2
See the UDENYCA on-body injector in action
For complete application information, please see the Instructions for Use.
Turn your phone sideways for an ideal viewing experience.
Help prevent febrile neutropenia in 4 steps1
For complete application information and instructions on how to use the UDENYCA® on-body injector, please see the Instructions for Use.
- FIRST OF ITS KIND*
UDENYCA PREFILLED AUTOINJECTOR
User-friendly features promote successful at-home or in-office delivery
Help prevent febrile neutropenia while administering in less than 10 seconds per cycle5
*For pegfilgrastim-product administration in the United States.
DESIGNED BY
A leading developer and manufacturer of injection systems with over 35 years of global experience
Simple administration with 2 clicks6
For complete administration directions, please see the Instructions for Use. Only adults can administer UDENYCA with the prefilled autoinjector.
- Hold the autoinjector with the clear cap facing up and pull the cap straight off.
- Press the autoinjector firmly against the skin and you will hear the first “click.”
- After you hear the second “click,” continue to hold the autoinjector in place and count to 5.
See the UDENYCA autoinjector in action
For complete administration directions, please see the Instructions for Use.
Turn your phone sideways for an ideal viewing experience.
- UDENYCA
PREFILLED SYRINGE
Tried-and-true administration delivered in office by the care team*
Next-day visits to the clinic may increase comfort for some patients
Can be left at room temperature (68°–77°) for up to 48 HOURS before being discarded
*May be prescribed for at-home or in-office use.
Single-dose prefilled subcutaneous injection of 6 mg administered once per chemotherapy cycle
The UDENYCA prefilled syringe is not designed to allow for direct administration of doses less than 0.6 mL (6 mg), as the syringe does not bear graduation marks
Direct administration to pediatric patients weighing less than 45 kg, requiring dosing of less than 0.6 mL (6 mg), is not recommended due to the potential for dosing errors. For more information, please refer to the Prescribing Information.
- UDENYCA prefilled syringe has been administered to over 300,000 patients since launch.†5
†January 2019 through November 2023.
Choose the administration that works best for your patient’s individual needs
*Do not administer between 14 days before and 24 hours after cytotoxic chemotherapy.2
Supply you can count on for your patients
†January 2019 through November 2023. Includes prefilled syringe and autoinjector.
ACCESS & SUPPORT
UDENYCA SolutionsTM provides patient support services designed to remove hurdles to access UDENYCA®
HELPFUL RESOURCES
Find product information, research articles, and resources to share with your patients.